Literature DB >> 28867115

Precision Medicine and PET/Computed Tomography in Melanoma.

Esther Mena1, Yasemin Sanli2, Charles Marcus3, Rathan M Subramaniam4.   

Abstract

Recent advances in genomic profiling and sequencing of melanoma have provided new insights into the development of the basis for molecular biology to more accurately subgroup patients with melanoma. The development of novel mutation-targeted and immunomodulation therapy as a major component of precision oncology has revolutionized the management and outcome of patients with metastatic melanoma. PET imaging plays an important role in noninvasively assessing the tumor biological behavior, to guide individualized treatment and assess response to therapy. This review summarizes the recent genomic discoveries in melanoma in the era of targeted therapy and their implications for functional PET imaging. Published by Elsevier Inc.

Entities:  

Keywords:  Biomarker; Immunotherapy; Melanoma; Molecular imaging; Precision oncology; Targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28867115      PMCID: PMC5701665          DOI: 10.1016/j.cpet.2017.05.002

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  41 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

Review 2.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

3.  Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.

Authors:  Yulia Bronstein; Chaan S Ng; Patrick Hwu; Wen-Jen Hwu
Journal:  AJR Am J Roentgenol       Date:  2011-12       Impact factor: 3.959

Review 4.  Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.

Authors:  Katharina C Kähler; Axel Hauschild
Journal:  J Dtsch Dermatol Ges       Date:  2010-11-17       Impact factor: 5.584

Review 5.  Novel Targeted Therapies for Metastatic Melanoma.

Authors:  Wade T Iams; Jeffrey A Sosman; Sunandana Chandra
Journal:  Cancer J       Date:  2017 Jan/Feb       Impact factor: 3.360

6.  Augmentation effects of lymphocyte activation by antigen-presenting macrophages on FDG uptake.

Authors:  Masanori Shozushima; Reiko Tsutsumi; Kazunori Terasaki; Shigehiro Sato; Ryuji Nakamura; Kimio Sakamaki
Journal:  Ann Nucl Med       Date:  2003-10       Impact factor: 2.668

7.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Authors:  Antoni Ribas; Omid Hamid; Adil Daud; F Stephen Hodi; Jedd D Wolchok; Richard Kefford; Anthony M Joshua; Amita Patnaik; Wen-Jen Hwu; Jeffrey S Weber; Tara C Gangadhar; Peter Hersey; Roxana Dronca; Richard W Joseph; Hassane Zarour; Bartosz Chmielowski; Donald P Lawrence; Alain Algazi; Naiyer A Rizvi; Brianna Hoffner; Christine Mateus; Kevin Gergich; Jill A Lindia; Maxine Giannotti; Xiaoyun Nicole Li; Scot Ebbinghaus; S Peter Kang; Caroline Robert
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

Review 8.  The natural course of cutaneous melanoma.

Authors:  Ulrike Leiter; Friedegund Meier; Birgit Schittek; Claus Garbe
Journal:  J Surg Oncol       Date:  2004-07-01       Impact factor: 3.454

Review 9.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

10.  Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.

Authors:  Bartosz Chmielowski
Journal:  J Skin Cancer       Date:  2013-04-21
View more
  5 in total

1.  PET Imaging of Melanoma Using Melanin-Targeted Probe.

Authors:  Xiaowei Ma; Zhen Cheng
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Precision Nuclear Medicine: The Evolving Role of PET in Melanoma.

Authors:  Chadwick L Wright; Eric D Miller; Carlo Contreras; Michael V Knopp
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

3.  Development of Dual Receptor Enhanced Pre-Targeting Strategy-A Novel Promising Technology for Immuno-Positron Emission Tomography Imaging.

Authors:  Lingyi Sun; Yongkang Gai; Zhonghan Li; Xiaohui Zhang; Jianchun Li; Yongyong Ma; Huiqiang Li; Ramon J Barajas; Dexing Zeng
Journal:  Adv Ther (Weinh)       Date:  2021-08-21

4.  The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma.

Authors:  Jesper A S Andersen; Anders D Spatzek; Mie H Vilstrup; Peter Grupe; Søren Hess; Paw C Holdgaard; Lars Bastholt; Oke Gerke; Malene G Hildebrandt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-07       Impact factor: 10.057

5.  Whole-Body versus Routine Skull Base to Mid-thigh 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography in Patients with Malignant Melanoma.

Authors:  Savas Ozdemir; Barry McCook; Christopher Klassen
Journal:  J Clin Imaging Sci       Date:  2020-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.